AbbVievsZevra Therapeutics

ABBV and ZVRA stock compared: price, dividend, valuation and results, from SEC filings.

ZVRA

Zevra Therapeutics, Inc.

$9.07

Value $533M

-2.26%
ZVRA's page

AbbVie (ABBV) has a market value of $501B and Zevra Therapeutics (ZVRA) $533M. Over the last year, with dividends, ABBV moved +24.9% and ZVRA -6.5%. The P/E is 48.7 for ABBV and 7.0 for ZVRA. Dividend yield: ABBV 2.44%, ZVRA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$501B

    ZVRA$533M

    ABBV is 941 times ZVRA

  • Revenue, 12 months

    ABBV$66.0B

    ZVRA$148M

    ABBV is 447 times ZVRA

  • Net income, 12 months

    ABBV$10.3B

    ZVRA$78M

    ABBV is 133 times ZVRA

  • Operating margin

    ABBV32.2%

    ZVRA60.8%

    28.6 points apart

  • ROIC

    ABBV25.7%

    ZVRA36.3%

    10.6 points apart

  • P/E

    ABBV48.7

    ZVRA7.0

    ABBV is 7.0 times ZVRA

  • Dividend yield

    ABBV2.4%

    ZVRA0.0%

    2.4 points apart

  • 5-year return

    ABBV+189.6%

    ZVRA+9.4%

    180.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+189.6%

ZVRA+9.4%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsZVRAWith dividends
1 year since November 18, 2025+24.9%Price +21.2%-6.5%Price -6.5%
3 years since November 17, 2023+126.7%+31.4% a yearPrice +105.0%+109.0%+27.9% a yearPrice +109.0%
5 years since November 18, 2021+189.6%+23.7% a yearPrice +142.2%+9.4%+1.8% a yearPrice +9.4%
10 years since November 21, 2016+605.5%+21.6% a yearPrice +369.3%-86.2%-18.0% a yearPrice -86.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieZVRAZevra Therapeutics

Valuation

ABBVZVRA
Valuation
Price$283.54$9.07
Market value$501B$533M
Enterprise value (EV)$571B$337M
P/E48.77.0
P/E, 5-year median57.0–
P/B–2.2
EV/EBIT26.93.8
Free cash flow yield3.8%7.2%

Results and growth

ABBVZVRA
Results and growth
Revenue, 12 months$66.0B$148M
Net income, 12 months$10.3B$78M
Free cash flow, 12 months$18.9B$38M
Earnings per share, 12 months$5.81$1.19
Revenue growth, year on year8.6%350.9%
Revenue growth a year, past+5.9%over 5 years+51.6%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVZVRA
Margins and returns on capital
Gross margin73.7%95.4%
Operating margin32.2%60.8%
Net margin15.7%52.8%
ROIC25.7%36.3%
ROE–41.1%

Balance sheet

ABBVZVRA
Balance sheet
Cash$10.8B$196M
Total debt$80.9B$1.2M
Net debt / EBITDA3.2-2.1
Interest cover7.1×24.6×

Dividends and buybacks

ABBVZVRA
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or ZVRA

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Zevra Therapeutics?

By market value, AbbVie ($501B) is about 941.5 times Zevra Therapeutics ($533M), at today's prices.

How did ABBV and ZVRA stock do over the last 10 years?

Since November 21, 2016, ABBV's price moved +369.3% and ZVRA's -86.2%. With dividends: ABBV +605.5% (+21.6% a year), ZVRA -86.2% (-18.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or ZVRA?

The dividend yield at today's price is 2.44% for AbbVie and none for Zevra Therapeutics. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and ZVRA?

At today's price, the P/E is 48.7 for ABBV and 7.0 for ZVRA. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, AbbVie or Zevra Therapeutics?

Over the last twelve months, the net margin was 15.7% for AbbVie and 52.8% for Zevra Therapeutics, and the operating margin 32.2% and 60.8%. Revenue was $66.0B and $148M.

Which is the better investment, AbbVie or Zevra Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.